Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388605 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| Cysteamine SCHEMBL28277491 | 0.92 | PTGS1 (0.40) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL8352097 | 0.85 | PTGS1 (0.55) | PTGS1SLC7A11MMP2SLC15A1CA12 | |
| SCHEMBL28400301 | 0.84 | KDM4E (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| Diacetamide SCHEMBL28020314 | 0.80 | PTGS1 (0.70) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL11888829 | 0.79 | CRBN (0.40) | KDM4EMAPTPTGS2THPOCRBN | |
| SCHEMBL29019106 | 0.79 | PTGS1 (0.54) | PTGS1SLC7A11MMP2SLC15A1CA12 | |
| SCHEMBL29616775 | 0.79 | CRBN (0.40) | KDM4EMAPTPTGS2THPOCRBN | |
| SCHEMBL28240743 | 0.79 | PTGS1 (0.54) | PTGS1SLC7A11MMP2SLC15A1CA12 | |
| SCHEMBL14725064 | 0.79 | SLC15A1 (0.42) | CRBNSLC15A1CA1CA2TAS2R38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350283-B2 | Methods and compositions for treating motor neuron diseases | UNIVERSITAT DE VALENCIA-ESTUDI GENERAL (ES) | 2025-07-08 | — | — | US | claimed |
| EP-4093389-A1 | PRODRUG FOR THE TREATMENT OF DISEASE AND INJURY OF OXIDATIVE STRESS | NaCuity Pharmaceuticals, Inc. (US) | 2022-11-30 | — | — | EP | claimed |
| US-20220160745-A1 | METHODS AND COMPOSITIONS FOR TREATING MOTOR NEURON DISEASES | UNIVERSITAT DE VALÈNCIA-ESTUDI GENERAL (ES) | 2022-05-26 | — | — | US | claimed |
| EP-3842040-B1 | METHODS AND FORMULATIONS FOR TREATMENT OF AND/OR PROTECTION AGAINST ACUTE LIVER FAILURE AND OTHER HEPATOTOXIC CONDITIONS | EGETIS THERAPEUTICS AB (SE) | 2022-03-09 | — | — | EP | claimed |
| EP-3930728-A1 | METHODS AND COMPOSITIONS FOR TREATING MOTOR NEURON DISEASES | Universitat de Valencia - Estudi General (ES) | 2022-01-05 | — | — | EP | claimed |
| EP-3402475-B1 | METHODS AND FORMULATIONS FOR TREATMENT OF AND/OR PROTECTION AGAINST ACUTE LIVER FAILURE AND OTHER HEPATOTOXIC CONDITIONS | EGETIS THERAPEUTICS AB (SE) | 2021-10-20 | — | — | EP | claimed |
| WO-2021151044-A1 | PRODRUG FOR THE TREATMENT OF DISEASE AND INJURY OF OXIDATIVE STRESS | NACUITY PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | claimed |
| EP-3122342-B1 | METHOD FOR THE PREPARATION OF N-ACETYL CYSTEINE AMIDE | NACUITY PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | claimed |
| EP-3019164-B1 | USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF PENETRATING HEAD INJURY | GOLDSTEIN GLENN A (US) | 2020-08-19 | — | — | EP | claimed |
| EP-2976061-B1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD (BE) | 2019-10-16 | — | — | EP | claimed |
| EP-2841064-B1 | USE OF N-ACETYLCYSTEINE AMIDE IN THE TREATMENT OF CATARACTS | SENTIENT LIFESCIENCES INC (US) | 2019-06-12 | — | — | EP | claimed |
| EP-2976061-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | Dentalmed Pharm Holding Ltd. (BE) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147613-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2014-09-25 | — | — | WO | claimed |
| US-12617747-B2 | Cannabinoid analogs and methods for their preparation | INMED PHARMACEUTICALS INC. (CA) | 2026-05-05 | — | — | US | disclosed |
| EP-4469044-B1 | IONIC-LIQUID-BASED FORMULATIONS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES | UNIV AVEIRO (PT) | 2026-04-08 | — | — | EP | disclosed |
| US-12514845-B2 | Ionic-liquid-based formulations for the prevention or treatment of neurological diseases | UNIVERSIDADE DE AVEIRO (PT) | 2026-01-06 | — | — | US | disclosed |
| EP-2976061-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | Dentalmed Pharm Holding Ltd. (BE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147613-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2014-09-25 | — | — | WO | disclosed |
| EP-2408441-A1 | COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS | Genmedica Therapeutics SL (ES) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106083-A1 | COMBINATION THERAPIES FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617747-B2 | Cannabinoid analogs and methods for their preparation | CNR2, CNR1, FAAH | PTGS1 2647/4885SLC7A11 4463/4885KDM4E 2119/4885 |
| US-20220160745-A1 | METHODS AND COMPOSITIONS FOR TREATING MOTOR NEURON DISEASES | SMN1; SMN2, NNMT, PDE4A | PTGS1 67/4885SLC7A11 436/4885KDM4E 1642/4885 |
| US-12350283-B2 | Methods and compositions for treating motor neuron diseases | SMN1; SMN2, NNMT, PDE4A | PTGS1 67/4885SLC7A11 436/4885KDM4E 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.